Bone Mineral Density News and Research

RSS

Polyphenols affect nutrient absorption: Study

Health benefits from polyphenol antioxidants - substances found in many fruits and vegetables - may come at a cost to some people. Penn State nutritional scientists found that eating certain polyphenols decreased the amount of iron the body absorbs, which can increase the risk of developing an iron deficiency.

24 Aug 2010

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

23 Aug 2010

Study finds occurrence of low BMD in inflammatory bowel disease patients

A thesis from the University of Gothenburg (Sweden) is the first in Scandinavia to study the occurrence of low bone mineral density in children and teenagers with inflammatory bowel disease. Half of the patients in the study showed signs of low bone mineral density.

23 Aug 2010

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

SRI International, an independent nonprofit research and development organization, announced today that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company. Further clinical development will focus on the lead compound's registration for the treatment of tamoxifen and aromatase inhibitor-resistant breast cancers.

20 Aug 2010

New research explores effects of radiation on human bone after stereotactic radiosurgery

New research holds promise for the thousands of people whose cancer has spread to their bones.A common treatment for such patients is radiation surgery even though very little is known about radiosurgery's impact on bone strength, says Edmond Richer, associate professor of engineering at Southern Methodist University in Dallas.

18 Aug 2010

Study finds low carbohydrate diet may help improve cardiovascular risk factors

The effectiveness of a low-carbohydrate diet versus a low-fat diet for weight loss have been frequently debated. According to a new study published in Annals of Internal Medicine, both diets produce identical weight loss when coupled with comprehensive behavior treatment, but a low-carbohydrate diet may help improve cardiovascular risk factors.

3 Aug 2010

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Osteologix, Inc. through its wholly owned Irish subsidiary Osteologix Limited and the Servier Research Group, the leading French independent pharmaceutical company, today announced that Osteologix has granted Servier an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. NB S101 is an innovative molecule acting on both bone formation and bone resorption.

2 Aug 2010

Aggressive prostate cancer patients tend to retain denser bones

Men who develop prostate cancer, especially the more aggressive and dangerous forms that spread throughout the body, tend to retain denser bones as they age than men who stay free of the disease, suggests new research from Johns Hopkins and the National Institute on Aging (NIA), part of the National Institutes of Health.

29 Jul 2010

Repros granted IRB approval to commence low dose Proellex study

Repros Therapeutics Inc. today announced it has received IRB approval to commence the low dose Proellex® study. The contract for clinical services was previously awarded to ICON. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion. The study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. In previous studies a 12.5 mg dose was well tolerated and yielded statistically significant efficacy signals for both uterine fibroids and endometriosis.

22 Jul 2010

Researchers issue a call to improve prevention, treatment of osteoporosis

A comprehensive Argentinean epidemiological study reveals the staggering costs of osteoporosis in the country.

15 Jul 2010

Data shows potential health benefits of S-equol in relieving menopausal symptoms

The findings of a scientific conference examining the growing body of research and potential health benefits of S-equol were published this month in the Journal of Nutrition. Manuscripts based on presentations made at the conference, which was organized by the Life Sciences Research Office, reveal data that S-equol is a safe, natural and effective solution to providing relief of menopausal symptoms such as hot flashes and muscle discomfort.

9 Jul 2010

Dietary protein intake may reduce bone density in overweight, postmenopausal women: Research

Overweight and moderately obese postmenopausal women using diets based on higher protein intake also need to be aware of potential bone loss, according to new research from Purdue University.

8 Jul 2010

Nearly 60% of Ontarians with rheumatoid arthritis fail to receive needed care from specialists: Study

Nearly 60 per cent of Ontarians with rheumatoid arthritis - an autoimmune disease that causes chronic inflammation of the joints - were not seen by a specialist within a one year period to treat the debilitating disease, according to a new study. Even more concerning is that women of child-bearing age are less likely to see a specialist than women 45 or older, say researchers from St. Michael's Hospital, the Institute for Clinical and Evaluative Sciences, and Women's College Hospital

7 Jul 2010

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

2 Jul 2010

Cartilage loss plays a role in development of OA, study says

A recent study determined that bone area predicted the development of medial (inner side) and lateral (outer side) knee cartilage damage and loss of medial cartilage volume. Subchondral bone mineral density (BMD) was associated with medial defect development but not cartilage loss. Researchers believe subchondral bone changes and loss of cartilage contribute to the development of osteoarthritis (OA).

28 Jun 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010

EVISTA improves bone quality as measured by HRpQCT: IIT

Interim data from a prospective Investigator Initiated Trial presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA (raloxifene 60mg; once-daily, distributed in 34 countries by DAIICHI SANKYO), indicated for the treatment and prevention of osteoporosis in postmenopausal women, improves bone quality as measured by the high-resolution peripheral quantitative computed tomography.

28 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Recommended supplementation not sufficient to normalise vitamin D levels in RA patients: Study

Two separate studies have shown that vitamin D deficiency is common in patients with a range of rheumatic diseases, with over half of all patients having below the 'normal' healthy levels of vitamin D (48-145 nmol/L) in their bodies. A further study assessing response to vitamin D supplementation found that taking the recommended daily dose did not normalise vitamin D levels in rheumatic disease patients.

18 Jun 2010

Growth hormone treatment promotes growth in infants with CRF: Study

Infants with chronic renal failure grow slowly, a problem that usually improves with aggressive nutritional therapy. When it doesn't, growth hormone is a safe and effective treatment to promote growth, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology.

4 Jun 2010

Bone Mineral Density News and Research

Polyphenols affect nutrient absorption: Study

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Study finds occurrence of low BMD in inflammatory bowel disease patients

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

New research explores effects of radiation on human bone after stereotactic radiosurgery

Study finds low carbohydrate diet may help improve cardiovascular risk factors

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Aggressive prostate cancer patients tend to retain denser bones

Repros granted IRB approval to commence low dose Proellex study

Researchers issue a call to improve prevention, treatment of osteoporosis

Data shows potential health benefits of S-equol in relieving menopausal symptoms

Dietary protein intake may reduce bone density in overweight, postmenopausal women: Research

Nearly 60% of Ontarians with rheumatoid arthritis fail to receive needed care from specialists: Study

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Cartilage loss plays a role in development of OA, study says

Merck challenges New York jury decision in federal FOSAMAX retrial

EVISTA improves bone quality as measured by HRpQCT: IIT

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Recommended supplementation not sufficient to normalise vitamin D levels in RA patients: Study

Growth hormone treatment promotes growth in infants with CRF: Study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News